Segmental surgery linked to 24% metachronous cancer rate in Lynch syndrome

In this institutional cohort of 450 people with Lynch syndrome and colorectal cancer, 24% of those having segmental resection later developed another colorectal cancer, compared with 5% after extended resection. The comparison is observational, so differences between the groups may explain part of the gap.

The study at a glance

Study design	Prospective cohort study using an institutional database
Who took part	450 patients with Lynch syndrome diagnosed with colorectal cancer between 1969 and 2024
What was tested	Segmental resection, extended resection, or no surgery
What was measured	Metachronous colorectal cancer, meaning a new colorectal cancer diagnosed after the first one; 10-year overall survival was also analysed

What this study measured

This study examined surgical choices after a first colorectal cancer diagnosis in people with Lynch syndrome, an inherited condition caused by variants in DNA-repair genes and associated with a high lifetime risk of colorectal and several other cancers. The question was whether the amount of colon removed at the first operation was associated with the chance of a later, separate colorectal cancer.

The team queried a prospectively maintained institutional database for 450 people with Lynch syndrome diagnosed with colorectal cancer from 1969 through 2024. They counted metachronous colorectal cancers, meaning new colorectal cancers diagnosed after the first cancer, rather than a recurrence at the original tumour site. They also analysed 10-year overall survival, although the supplied abstract does not report the survival estimates.

Of the 450 patients, 350 had a segmental resection, which removes the cancer-bearing section of bowel and reconnects the remaining bowel where possible. Forty had an extended resection, removing a larger amount of colon. Sixty did not undergo surgery. Those groups are clinically different populations, and the no-surgery group should not be read as a competing surgical strategy.

This was a cohort study, not a randomised trial. The researchers followed outcomes recorded over time, but they did not assign patients by chance to segmental or extended surgery. It can show an association between surgical approach and later cancer diagnoses. It cannot prove that the extent of surgery itself caused the observed difference.

Later cancers were more frequent after segmental resection

Overall, 88 of 450 patients, or 20%, developed a metachronous colorectal cancer. The median time between the first and later cancer diagnoses was 13 years. Half of the intervals fell between 5 and 20 years, reported as the interquartile range.

Among people who had segmental resection, 83 of 350, or 24%, developed a later colorectal cancer. The corresponding figure was 2 of 40, or 5%, among those who had extended resection. Three of 60 people who did not have surgery also developed a metachronous cancer.

These figures fit the biological concern behind extended colectomy in Lynch syndrome. A segmental operation leaves more colon at risk, while an extended operation leaves less. But the numbers alone do not tell us how much of the difference arose from the operation. A patient offered extended surgery may differ from one offered segmental surgery in ways that also affect later-cancer risk, including age, tumour location, family history, gene variant, health at diagnosis, surveillance, and the treatment era.

The long median interval is also clinically relevant. A later cancer risk can remain present well beyond the years immediately after treatment. It does not tell us the risk for an individual person at a given point in time, and it does not establish which surveillance schedule is best.

The Lynch gene variant was strongly associated with risk

The investigators grouped MLH1 and MSH2 variants as higher-risk genes, and MSH6 and PMS2 variants as lower-risk genes. Metachronous colorectal cancer occurred in 80 of 326 people with an MLH1 or MSH2 variant, 25%, compared with 8 of 124 people with an MSH6 or PMS2 variant, 6%.

That contrast is one reason a single surgical rule for everyone with Lynch syndrome can be hard to defend. The gene involved is associated with future cancer risk, but the study does not establish that gene status alone should determine the operation. Surgical decisions also involve the existing cancer, remaining bowel function, age, other illnesses, prior operations, personal priorities, and the possibility of future treatments.

I would be careful not to turn the lower rate in the MSH6/PMS2 group into reassurance that a second cancer cannot occur. Six percent is a group-level result in this particular cohort over a long and variable period of follow-up. Likewise, a 25% rate in the higher-risk group does not predict any one person’s outcome.

What the paper cannot settle about surgery

The paper addresses later colorectal cancers, which are an important outcome, but they are not the same as overall survival. Avoiding a metachronous cancer could prevent another diagnosis, operation, and treatment. Whether extended surgery improves how long people live requires survival data that account for competing causes of death and differences between surgical groups. The supplied abstract says the investigators analysed 10-year overall survival, but provides no numerical results for it.

Selection differences are the central limitation. The database spans 55 years, during which Lynch testing, colonoscopy quality, operative techniques, pathology, chemotherapy, and immunotherapy all changed. A person treated in an earlier era may have had different genetic testing, surveillance, and surgical options from a person treated recently. The distribution of Lynch genes, ages, and cancer characteristics may also have differed between the segmental and extended-resection groups.

The extended-resection group was small, with only 40 people and two later cancers. That makes its 5% estimate less precise than the segmental group’s estimate, but the abstract does not provide confidence intervals. The study also does not report bowel-function outcomes or quality of life in the supplied material. Those consequences matter because removing more colon can bring long-term changes in stool frequency, urgency, and daily life.

For me, the useful reading is narrower than a verdict for either operation. This cohort supports the view that future colorectal-cancer risk differs across Lynch syndrome and may be higher after segmental resection. It does not demonstrate an overall survival advantage from extended surgery, nor does it show that one approach is right for every patient.